WVE

Wave Life Sciences, Inc.

NASDAQ· Healthcare· Biotechnology

$5.04-2.33%

Key metrics

Market cap: $993.12M
P/E: —
Forward P/E: —
P/B: 1.8x
Dividend yield: —
EPS: -$1.05
ROE: -67.42%
Profit margin: 0.00%
Revenue growth: -73.90%
Beta: -1.29
52-week high: $21.73
52-week low: $5.01

History

How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.

Equity, revenue and profitEquityRevenueNet income

The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.

Revenue4 years

Net debtDebt minus cash — below zero means more cash than debt

Investors holding this

Major managers that reported this stock in their latest 13F.

About the company

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Employees: 317
Headquarters: Cambridge, United States
Website: wavelifesciences.com

Company description provided by Yahoo Finance.